Episomal Plasmid Reprogramming of Blood Cells for iPSC Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) from somatic cells face challenges in efficiency, genomic stability, and invasiveness, particularly when using skin-derived fibroblasts, which are prone to environmental mutations and require invasive procedures.
Innovation Solution
A method utilizing non-integrating episomal plasmid vectors to reprogram blood cells, specifically peripheral blood mononuclear cells (PBMCs), with reprogramming factors like Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40 Large T Antigen, and shRNA-p53, encoded in oriP/EBNA1 vectors, cultured on treated cell surfaces with extracellular matrix proteins, to achieve stable and efficient generation of iPSCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If skin biopsy is used to obtain fibroblasts for reprogramming, then reprogramming can be performed, but the procedure is invasive and requires cell expansion before experimentation
Solution Approach 1:
The patent inverts the conventional approach by using blood cells (which are easily accessible through simple venipuncture) instead of skin fibroblasts (which require invasive biopsy). This inversion transforms the cell source from difficult-to-obtain to easily-obtain, eliminating the need for invasive procedures and pre-culture expansion while maintaining reprogramming capability
Solution Approach 2:
The patent uses blood-derived cells as a surrogate source that copies the essential reprogramming function without requiring the traditional skin biopsy route. Blood cells serve as a substitute that provides the same experimental utility (reprogramming to iPSCs) while avoiding the drawbacks of the original approach
2Reliability
If skin cells are used as the source material, then reprogramming can proceed, but the cells harbor more mutations due to environmental insults such as UV irradiation
Solution Approach 1:
The patent extracts the reprogramming function from skin cells and transfers it to blood cells, which are shielded from environmental insults like UV radiation. By taking out the essential reprogramming capability and applying it to a different cell type (blood cells) that naturally lack exposure to mutagenic environmental factors, the method achieves superior genomic stability
Solution Approach 2:
Blood cells serve as an intermediary source that mediates the reprogramming process without being directly exposed to environmental mutagens. These cells act as a protected intermediate stage that can be reprogrammed with high fidelity, avoiding the mutation burden accumulated in skin cells
3Productivity
If fibroblasts are used for reprogramming, then the process can be performed, but the reprogramming efficiency is low and time-consuming
Solution Approach 1:
The patent changes the fundamental parameter of cell source from skin fibroblasts to blood cells, which inherently possess different biological properties that favor faster and more efficient reprogramming. Blood cells require no pre-expansion and can be directly reprogrammed, dramatically reducing the time and increasing the efficiency of the overall process
Data Source
AI summary
Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.